| abstract |
The invention herein provides a monoclonal antibody that specifically binds to human plasmalemma vesicle-associated protein (PLVAP, PV-1) or a derivative thereof, comprising antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light chain variable region having amino acid sequences as set forth in SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19, respectively; and antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody heavy chain variable region having amino acid sequences as set forth in SEQ ID NO: 22, SEQ ID NO: 23 and SEQ ID NO: 24, respectively. The invention also provides a preparation process of a human-mouse chimeric antibody and amino acid sequences of the antibody heavy chain variable region and the antibody light chain variable region. The antibody or derivative thereof can be used as a component of a pharmaceutical composition or prepared into a suitable pharmaceutical preparation, administered alone or combined with other medications, such as anti-VEGF monoclonal antibody and the like for treating choroidal neovascularization fundus diseases and other angiogenesis/osmosis-related diseases. |